Hector F Bonilla, MD
Infectious Disease · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bonilla’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence C134184 · Current
Licensed to practise in California · since 2015 · expires 2028-08-31 · University of the Valley Division of Health Sciences.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$51,938
Medicare paid this office $51,938 for 242 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 202 | $39,962 | $152 |
| New patient visit (60+ min) | 26 | $4,812 | $185 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $4,782 | $106 |
Who their Medicare patients are
242 Original Medicare patients in 2024. Average age 64 · Under 65 38% · Women 72% · Also on Medicaid 24% · Health risk score 1.29. At or below the middle of the specialty; the typical infectious disease clinician is at 3.
Conditions among them: High blood pressure 45% · Depression 40% · Coronary heart disease 17% · Diabetes 14% · Chronic kidney disease 12% · Cancer 9% · Heart failure 6% · COPD 6% · Atrial fibrillation 6%.
The office billed $201,579, Medicare allowed $70,716 and paid $51,938; for 352 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 242 | 352 | 64 | 1.29 | $201,579 | $51,938 |
| 2023 | 234 | 462 | 64 | 1.43 | $256,766 | $50,695 |
| 2022 | 223 | 384 | 62 | 1.25 | $224,029 | $36,663 |
| 2021 | 207 | 572 | 62 | 1.23 | $220,814 | $40,808 |
| 2020 | 208 | 572 | 62 | 1.42 | $232,704 | $36,258 |
| 2019 | 221 | 321 | 62 | 1.35 | $258,802 | $30,935 |
| 2018 | 178 | 249 | 62 | 1.13 | $164,462 | $24,916 |
| 2017 | 130 | 397 | 65 | 2.31 | $86,940 | $30,352 |
| 2016 | 450 | 2,281 | 74 | 3.83 | $379,990 | $205,264 |
| 2015 | 245 | 1,510 | 71 | 3.17 | $226,765 | $133,975 |
| 2014 | 55 | 212 | 65 | 4.14 | $40,735 | $12,359 |
| 2013 | 131 | 475 | 69 | 2.65 | $89,894 | $26,668 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Long return visit (40+ min) | 140 | $26,075 | $159 |
| Return visit (30+ min) | 85 | $10,479 | $104 |
| New patient visit (60+ min) | 30 | $5,420 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $3,291 | $110 |
| Telehealth originating site facility fee | 96 | $2,240 | $21 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,794 | $120 |
2022: 3 services
| Return visit (30+ min) | 204 | $25,029 | $107 |
| New patient visit (60+ min) | 45 | $8,513 | $189 |
| Telehealth originating site facility fee | 80 | $1,806 | $19 |
2021: 4 services
| Return visit (30+ min) | 171 | $25,357 | $107 |
| New patient visit (60+ min) | 28 | $5,856 | $209 |
| Telehealth originating site facility fee | 187 | $5,162 | $19 |
| Telephone medical discussion with physician, 21-30 minutes | 31 | $3,547 | $101 |
2020: 5 services
| Return visit (30+ min) | 149 | $18,503 | $89 |
| Telephone medical discussion with physician, 21-30 minutes | 57 | $6,700 | $91 |
| Telehealth originating site facility fee | 165 | $4,761 | $20 |
| Long return visit (40+ min) | 40 | $3,879 | $97 |
| New patient visit (60+ min) | 11 | $1,924 | $175 |
2019: 2 services
| Return visit (30+ min) | 193 | $24,136 | $88 |
| New patient visit (60+ min) | 36 | $5,776 | $160 |
2018: 3 services
| Return visit (30+ min) | 110 | $13,213 | $86 |
| New patient visit (60+ min) | 39 | $6,967 | $179 |
| New patient visit (30+ min) | 43 | $3,431 | $80 |
2017: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $12,856 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $8,090 | $61 |
| Return visit (30+ min) | 50 | $4,078 | $69 |
| New patient visit (45+ min) | 27 | $2,896 | $107 |
| New patient visit (30+ min) | 30 | $2,037 | $68 |
2016: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 355 | $125,614 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 203 | $35,553 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 153 | $34,780 | $62 |
| Return visit (30+ min) | 24 | $4,121 | $92 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 11 | $1,120 | $80 |
2015: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 126 | $90,610 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $12,891 | $63 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 60 | $11,620 | $80 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $8,224 | $175 |
| Return visit (30+ min) | 35 | $4,553 | $95 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,298 | $118 |
2014: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 43 | $9,287 | $54 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,600 | $107 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $976 | $75 |
2013: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 98 | $19,501 | $54 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 66 | $5,559 | $76 |
| Short return visit (20+ min) | 11 | $455 | $38 |
| Short return visit | 13 | $305 | $19 |
Medicaid work
$25,270 in 2024
Medicaid paid $25,270 for 218 billed services this clinician did in 2024, up to 24 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 191 | $20,400 |
| New patient visit (60+ min) | 27 | $4,870 |
| 2024 | 218 | 2 | 24 | $25,270 |
| 2023 | 278 | 4 | 25 | $23,285 |
| 2022 | 26 | 2 | 13 | $716 |
| 2021 | 67 | 1 | 19 | $1,562 |
| 2020 | 110 | 2 | 17 | $2,467 |
| 2019 | 13 | 1 | 13 | $560 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 173 | $19,885 |
| Telehealth originating site facility fee | 63 | $1,603 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 27 | $1,221 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 15 | $576 |
2022
| Return visit (30+ min) | 13 | $411 |
| Telehealth originating site facility fee | 13 | $305 |
2021
| Telehealth originating site facility fee | 67 | $1,562 |
2020
| Telehealth originating site facility fee | 97 | $1,934 |
| Long return visit (40+ min) | 13 | $533 |
2019
| Return visit (30+ min) | 13 | $560 |
Drugs they prescribed that Part D paid
$81,460
Pharmacies billed $81,460 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 993) in 2024. At or below the middle of the specialty; the typical infectious disease clinician is at 0%.
952 generic and fewer than 11 brand-name prescriptions · $81,460 in drug cost · 143 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Aripiprazole | 306 | $12,069 | $39 |
| Colchicine | 69 | $11,125 | $161 |
| Valacyclovir | 82 | $8,703 | $106 |
| Hydroxychloroquine Sulfate | 117 | $5,059 | $43 |
| Famciclovir | 21 | $5,049 | $240 |
See all 13 drugs
| Aripiprazole | 306 | $12,069 | $39 |
| Colchicine | 69 | $11,125 | $161 |
| Valacyclovir | 82 | $8,703 | $106 |
| Hydroxychloroquine Sulfate | 117 | $5,059 | $43 |
| Famciclovir | 21 | $5,049 | $240 |
| Celecoxib | 97 | $2,751 | $28 |
| Valganciclovir | 31 | $2,545 | $82 |
| Leflunomide | 39 | $2,267 | $58 |
| Acyclovir | 54 | $1,297 | $24 |
| Naltrexone | 46 | $987 | $21 |
| Famotidine | 41 | $483 | $12 |
| Fludrocortisone Acetate | 11 | $216 | $20 |
| Sulfasalazine | 11 | $159 | $14 |
Year by year
| 2024 | 993 | 193 | 0% (0) | None | $81,460 |
| 2023 | 1,009 | 191 | 0% (0) | None | $106,829 |
| 2022 | 1,074 | 197 | 0% (0) | 2% | $136,187 |
| 2021 | 979 | 197 | 0% (0) | 3% | $144,318 |
| 2020 | 930 | 176 | 0% (0) | 7% | $197,650 |
| 2019 | 1,279 | 201 | 0% (0) | 6% | $269,391 |
| 2018 | 1,139 | 201 | 0% (0) | 10% | $386,000 |
| 2017 | 305 | 89 | 0% (0) | 7% | $145,857 |
| 2016 | 26 | None | 0% (0) | 69% | $26,536 |
| 2015 | 11 | None | None | None | $1,379 |
| 2014 | 36 | 12 | 0% (0) | None | $11,079 |
| 2013 | 98 | 29 | 0% (0) | 22% | $37,350 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Aripiprazole | 333 | $28,432 | $85 |
| Valganciclovir | 41 | $21,401 | $522 |
| Valacyclovir | 102 | $9,261 | $91 |
| Famciclovir | 32 | $8,453 | $264 |
| Hydroxychloroquine Sulfate | 139 | $6,791 | $49 |
| Colchicine | 43 | $4,388 | $102 |
| Mitigare | 11 | $3,962 | $360 |
| Leflunomide | 44 | $3,000 | $68 |
| Celecoxib | 86 | $2,744 | $32 |
| Acyclovir | 63 | $2,023 | $32 |
| Naltrexone | 48 | $1,593 | $33 |
| Gabapentin | 16 | $209 | $13 |
2022: 12 drugs
| Aripiprazole | 309 | $40,513 | $131 |
| Valganciclovir | 73 | $36,797 | $504 |
| Valacyclovir | 137 | $13,680 | $100 |
| Hydroxychloroquine Sulfate | 157 | $10,591 | $67 |
| Famciclovir | 47 | $8,257 | $176 |
| Colchicine | 39 | $6,508 | $167 |
| Leflunomide | 36 | $4,653 | $129 |
| Celecoxib | 90 | $3,922 | $44 |
| Naltrexone | 50 | $1,928 | $39 |
| Acyclovir | 60 | $1,723 | $29 |
| Trazodone | 11 | $158 | $14 |
| Spironolactone | 20 | $89 | $4 |
2021: 13 drugs
| Aripiprazole | 260 | $46,360 | $178 |
| Valganciclovir | 94 | $39,250 | $418 |
| Valacyclovir | 126 | $12,140 | $96 |
| Famciclovir | 51 | $9,507 | $186 |
| Hydroxychloroquine Sulfate | 154 | $9,417 | $61 |
| Leflunomide | 45 | $6,050 | $134 |
| Colchicine | 22 | $5,828 | $265 |
| Valtrex | 11 | $4,926 | $448 |
| Celecoxib | 68 | $3,015 | $44 |
| Naltrexone | 35 | $1,333 | $38 |
| Acyclovir | 47 | $1,318 | $28 |
| Spironolactone | 15 | $117 | $8 |
| Trazodone | 12 | $100 | $8 |
2020: 12 drugs
| Valganciclovir | 102 | $92,990 | $912 |
| Aripiprazole | 249 | $31,956 | $128 |
| Famciclovir | 60 | $14,527 | $242 |
| Valacyclovir | 139 | $12,929 | $93 |
| Hydroxychloroquine Sulfate | 138 | $12,542 | $91 |
| Valtrex | 12 | $9,629 | $802 |
| Colchicine | 24 | $8,767 | $365 |
| Leflunomide | 34 | $4,057 | $119 |
| Celecoxib | 52 | $3,708 | $71 |
| Acyclovir | 54 | $1,481 | $27 |
| Naltrexone | 29 | $918 | $32 |
| Trazodone | 12 | $66 | $6 |
2019: 10 drugs
| Valganciclovir | 131 | $134,291 | $1,025 |
| Aripiprazole | 322 | $38,956 | $121 |
| Hydroxychloroquine Sulfate | 240 | $23,774 | $99 |
| Valacyclovir | 220 | $19,091 | $87 |
| Famciclovir | 116 | $15,884 | $137 |
| Leflunomide | 49 | $9,768 | $199 |
| Colchicine | 34 | $7,669 | $226 |
| Acyclovir | 73 | $2,278 | $31 |
| Naltrexone | 36 | $1,091 | $30 |
| Trazodone | 11 | $48 | $4 |
2018: 11 drugs
| Valganciclovir | 196 | $261,565 | $1,335 |
| Hydroxychloroquine Sulfate | 247 | $25,733 | $104 |
| Colchicine | 43 | $20,813 | $484 |
| Famciclovir | 120 | $19,086 | $159 |
| Valacyclovir | 227 | $18,311 | $81 |
| Leflunomide | 86 | $17,914 | $208 |
| Aripiprazole | 19 | $2,360 | $124 |
| Acyclovir | 61 | $1,842 | $30 |
| Naltrexone | 48 | $1,735 | $36 |
| Celecoxib | 13 | $1,140 | $88 |
| Trazodone | 20 | $90 | $5 |
2017: 7 drugs
| Valganciclovir | 62 | $116,396 | $1,877 |
| Valacyclovir | 71 | $5,525 | $78 |
| Famciclovir | 36 | $5,505 | $153 |
| Hydroxychloroquine Sulfate | 30 | $4,672 | $156 |
| Leflunomide | 16 | $2,059 | $129 |
| Acyclovir | 34 | $1,164 | $34 |
| Trazodone | 12 | $77 | $6 |
2013: 2 drugs
| Doxycycline Hyclate | 13 | $2,204 | $170 |
| Vancomycin | 16 | $2,194 | $137 |
Money from drug and device companies
$247 in 2025
| 2025 | 2 | 2 | None | $247 |
| 2024 | 1 | 11 | $4,828 | $6,052 |
| 2022 | 1 | 4 | $1,610 | $1,841 |
| 2019 | 1 | 1 | None | $99 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
See all 2 published payments
| Pfizer | Meals · 2025-10-21 | Abrysvo | $136 |
| Invivyd | Meals · 2025-10-20 | Pemgarda | $111 |
See earlier years (2024, 2022, 2019)
2024: $6,052
| Gilead Sciences | Veklury | $6,052 | 11 payments
|
2022: $1,841
| Gilead Sciences | None | $1,841 | 4 payments
|
2019: $99
| Astellas Pharma US | None | $99 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1225115371
- Licence
- CA C134184California C134184: Current · expires 2028-08-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- OH 2278833
- Taxonomy
- Federal specialty code 207RI0200X (207RI0200X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-11-01
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.